Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.
11,921.50-96.9
Stock Analysis, IPO, Mutual Funds, Bonds & More

Cipla announces closure of USFDA inspection at Bengaluru facility

The company had earlier said that USFDA issued seven observations after conducting a routine 'CGMP inspection' at Cipla's API manufacturing facility in Virgonangar, Bengaluru.

PTI|
Sep 22, 2019, 05.20 PM IST
0Comments
BCCL
Tablets---BCCL
Representative Image
NEW DELHI: Cipla Ltd on Sunday announced the closure of inspection by the US health regulator at the company's API manufacturing facility in Bengaluru.

"Following the inspection by the United States Food and Drug Administration (USFDA) at Company's API manufacturing facility in Virgonagar, Bengaluru, from July 15- 19, 2019, the company has received the Establishment Inspection Report (EIR), indicating closure of the inspection," the company said in a filing to the BSE.

The company had earlier said that USFDA issued seven observations after conducting a routine 'CGMP inspection' at Cipla's API manufacturing facility in Virgonangar, Bengaluru.

Also Read

Strides Pharma gets USFDA inspection report for Alathur unit with no adverse observations

Jubilant Life slips 4% on USFDA inspection

USFDA inspection of Biocon's drug substance unit at Bengaluru complete

USFDA inspects Dahej facility, no observations issued: Ajanta Pharma

Comments
Add Your Comments
Commenting feature is disabled in your country/region.
Download The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.

Other useful Links


Follow us on


Download et app


Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service